CD274 and melanoma: It was reported that 33% of melanoma patients achieved complete response when treated with the combination of dabrafenib and trametinib with spartalizumab (anti-PD-L1-antibody); the 1-year OS was 86%; however, the number of grade ≥3 adverse events was 75% [119].